Meet Kimberly Roosevelt: JDRF 2015 Children’s Congress Chair

It is JDRF Advocacy’s great honor to announce that Kimberly C. Roosevelt, of Dallas, Texas, will serve as chair of JDRF 2015 Children’s Congress to be held in Washington, D.C., this July. Kim, a prominent JDRF Advocate and volunteer leader, and mother to 13-year-old Elizabeth who lives with type 1 diabetes (T1D), will welcome more […]

Investigating the Role of Regulatory T Cells in T1D

A video explains a potential new immune therapy in the words of the T1D investigator and one of the clinical study participants JDRF Research in the Field spoke to the lead investigator, Dr. Stephen Gitelman at the University of California San Francisco’s Children’s Hospital, who enrolled 14 people recently diagnosed with Type 1 Diabetes (T1D) […]

Next-Generation Artificial Pancreas System Launches

Medtronic’s New MiniMed®640G Artificial Pancreas System Predicts and Helps Prevent Deadly Low Glucose Emergencies A four year-old Australian boy with type 1 diabetes (T1D) is the first person to use a groundbreaking commercial artificial pancreas system that can predict and automatically prevent low blood-glucose emergencies. Medtronic’s MiniMed® 640G is an insulin pump/continuous glucose monitor combination […]

JDRF and Janssen to Drive Novel Type 1 Diabetes Research Concept

Planned Collaboration Will Focus on Type 1 Diabetes “Disease Interception” – Whose Aim is to Prevent Insulin Dependence JDRF recently announced its support of an innovative scientific approach of Janssen Research & Development, LLC (Janssen) and the company’s Disease Interception Accelerator (DIA) group, designed to support novel initiatives of disease interception – or changing the […]

T1D Trial Looks to Teach an Old Drug New Tricks

JDRF-funded clinical study of a drug called TUDCA looks to improve beta cell functioning in people recently diagnosed with T1D Until recently, much of type 1 diabetes (T1D) research has focused on suppressing the autoimmune system to prevent or reverse disease, but this approach has been slow to yield promising, long-term results in people with […]

Re-educating the Immune System in T1D

JDRF partner Selecta developed a novel technology for creating a T1D vaccine to potentially halt the disease process It has been more than 30 years since scientists identified the basic autoimmune feature of type 1 diabetes (T1D) when they discovered autoantibodies binding to targets from cells in the pancreas. And yet, devising therapies to halt […]

Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]